How X-Ray Offered Peek Inside 2,000-Year-Old Herculaneum Scroll
Researchers have revealed the identity of the author behind a charred scroll from the first century BC, thanks to the advanced X-ray technology. Found in the ancient Roman town of Herculaneum, the scroll contains part of a multi-volume work titled "On Vices" and was written by an ancient Greek philosopher, Philodemus.
The charred scroll was recovered from a Roman villa, believed to have been the home of Julius Caesar's father-in-law. The scroll, along with the villa, was buried during the eruption of Mount Vesuvius nearly 2,000 years ago.
Using the X-ray, the researchers were able to look inside the burned scroll, which was made up of ancient paper called carbonised papyrus. They virtually unwrapped the scroll and, for the first time with this method, managed to uncover important details such as the title and the author. This was made possible because the X-ray images revealed traces of ink lettering.
Dr Michael McOsker, a papyrologist at University College London, told The Guardian, "It's the first scroll where the ink could just be seen on the scan. Nobody knew what it was about. We didn't even know if it had writing on." It is one of the three ancient scrolls from Herculaneum now kept at the Bodleian Library at Oxford.
Many ancient scrolls have been discovered earlier and are currently kept at the National Library of Naples. But when researchers attempted to open them and read, they couldn't, for the scrolls were burned during the volcanic eruption. Even the ink is hard to read on the black, carbonised papyrus.
So, in 2023, a Vesuvius Challenge was launched worldwide to help read the Herculaneum scrolls using 3D X-rays technology. It carried an award for anyone who could successfully decode the ancient texts.
Last year, a group of tech-savvy students won $700,000 (approx. Rs 6 crore) grand prize for using artificial intelligence software that allowed them to decode 2,000 Greek letters from another scroll.
Dr Brent Seales, a computer scientist at the University of Kentucky who co-founded the Vesuvius Challenge, said, "We're seeing evidence of ink in many of the new scrolls we've scanned, but we haven't converted that into coherent text yet."
"That's our current bottleneck: converting the massive scan data into organised sections that are properly segmented, virtually flattened, and enhanced so that the evidence of ink can then be interpreted as actual text," he added.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
12 hours ago
- Time of India
Alzheimer's disease: A blood test can detect early symptoms, finds study
Imagine getting tested for Alzheimer's with just a simple blood draw instead of going through complicated brain scans or spinal taps. Sounds like the future, right? Well, it's pretty much here. Researchers at the Mayo Clinic in the U.S. have been working on a new blood test that can accurately detect early signs of Alzheimer's disease, and the results are seriously impressive. This test looks at two specific proteins in your blood—amyloid beta 42/40 and p-tau217—both of which are linked to that gunky buildup in the brain called amyloid plaques, a telltale sign of Alzheimer's. So how accurate is it? Try 95% sensitivity, meaning it correctly identifies people who do have memory problems 95% of the time. That's pretty hard to beat. It also has 82% specificity, which means it's also really good at ruling out people who don't have Alzheimer's. What's even better? This isn't just lab testing. The study was done on over 500 real patients in a memory clinic—so it's based on actual, day-to-day medical situations, not just controlled experiments. Dr. Gregg Day, who led the study (published in Alzheimer's & Dementia journal), said this new blood test works just as well as the more invasive and expensive options we currently use. "It's about as accurate as spinal fluid testing," he told The Guardian, 'but way easier, less painful, and much cheaper.' In people who had Alzheimer's, the levels of p-tau217 were clearly higher compared to those who didn't, which helped the team confirm the diagnosis confidently. The best part? This blood test has already gotten the green light from the U.S. FDA—so it's not just theory anymore, it's actually available. 6 million Americans are living with Alzheimer's disease Alzheimer's disease is becoming a huge concern across the U.S.—and it's not just about forgetfulness in old age. It's a progressive brain disorder that slowly chips away at memory, thinking skills, and the ability to do everyday tasks. Right now, more than 6 million Americans are living with Alzheimer's, and that number is expected to nearly double by 2050. Most people with Alzheimer's are 65 or older, but it can also hit younger adults in what's called early-onset Alzheimer's. The biggest risk factor is age, but family history and genetics also play a role. The disease usually starts slow—maybe forgetting names or getting lost in familiar places—and worsens over time. The best part is science is catching up. New blood tests and brain imaging tools are helping doctors catch the disease earlier than ever before. There are also a few new medications out that might slow down the progression if taken early enough. Next up, researchers want to test it on even more diverse groups of people and also those who might be in the very early stages of Alzheimer's but don't have any symptoms yet. In short: diagnosing Alzheimer's just got a whole lot simpler—and that could change everything when it comes to early intervention and treatment. One step to a healthier you—join Times Health+ Yoga and feel the change
Economic Times
21 hours ago
- Economic Times
This disease might be silently killing millions quietly, says research. Are you at risk?
A new international study has found that over 15 million people across the US, UK, Germany, and France are unknowingly living with metabolic dysfunction-associated steatohepatitis (MASH), the most aggressive form of fatty liver disease. Despite its serious risks—including liver failure, cancer, and other chronic illnesses—more than three-quarters of affected individuals remain undiagnosed. Researchers are urging wider screening, especially among those with obesity and type 2 diabetes, and highlighting the potential role of weight-loss medications in treatment. Tired of too many ads? Remove Ads Widespread but Largely Undetected Progressive and Potentially Fatal Tired of too many ads? Remove Ads Urgent Need for Diagnosis and Treatment Potential Role of Weight Loss Medications Risk Factors and Screening A recent international study has revealed that millions of people in the US and Europe may be unknowingly living with a dangerous form of fatty liver disease. Published in The Lancet Regional Health Europe, the research indicates that a vast number of individuals are affected by metabolic dysfunction-associated steatotic liver disease (MASLD), with the majority still study examined populations in the United States, United Kingdom, Germany, and France, and found that approximately 20 million people across these countries have the more severe variant of MASLD known as metabolic dysfunction-associated steatohepatitis (MASH). Alarmingly, only about 2.5 million have received a formal diagnosis. This means roughly three-quarters of those with the disease—an estimated 16.7 million individuals—remain unaware of their is the updated term for non-alcoholic fatty liver disease (NAFLD), and it affects people whose liver contains over 5% fat despite little or no alcohol intake. While many patients only develop the earliest and less severe stage known as simple fatty liver, the disease can progress without symptoms and cause serious damage over the aggressive form of the disease, is associated with inflammation and can lead to fibrosis, or scarring of the liver. If not managed, it may progress to cirrhosis, a stage marked by irreversible liver damage and potential liver failure. The condition is also linked to higher risks of cardiovascular issues, chronic kidney disease, and liver study's findings emphasize the urgency of early diagnosis, especially as MASH is particularly common among people with type 2 diabetes and those who are overweight or obese. Researchers noted that around two-thirds of individuals with type 2 diabetes are thought to have Jeffrey Lazarus, the lead author of the study, stressed the economic and health burden posed by undiagnosed MASH. He pointed out that without a significant increase in diagnosis and treatment, the financial costs to healthcare systems could triple over the next two Emmanouil Tsochatzis of University College London echoed this warning, stating that over 15 million people in the US and Europe are living with the most severe form of fatty liver disease without knowing it. He warned that both human suffering and economic consequences could worsen significantly if diagnosis rates do not MASH has been diagnosed through liver biopsy, but newer, non-invasive tools such as blood tests, ultrasound, and MRI scans have made screening easier. Experts now recommend that individuals with type 2 diabetes, obesity combined with other risk factors, or persistently elevated liver enzymes undergo regular study has also brought renewed attention to the potential of weight loss medications to help manage MASH. Dr. Paul Brennan, a hepatologist and co-author of the study, highlighted the promise of GLP-1 agonists like Wegovy and Mounjaro. These drugs work by reducing appetite and slowing digestion, leading to weight loss, which in turn may help reduce fat accumulation and scar tissue in the Betel, president of the Fatty Liver Alliance, stressed that individuals with type 2 diabetes or obesity are often not screened for MASH until significant liver damage has occurred. He called for broader liver health assessments and, when appropriate, the use of weight loss drugs as part of a comprehensive treatment strategy.A separate study released around the same time found that the diabetes drug dapagliflozin not only helps reduce blood sugar but also lowers fat and scarring in the liver, suggesting another potential treatment to health authorities like the NHS, those at greater risk of MASLD include people who are overweight, have type 2 diabetes, high blood pressure, high cholesterol, metabolic syndrome, or are over the age of 50. Smoking and thyroid disorders may also increase the typically begin diagnosis with blood tests that show elevated liver enzymes. If abnormalities are detected, further assessments such as imaging scans or liver elastography (FibroScan) are used to evaluate liver fat and fibrosis the growing prevalence of MASLD and MASH, the study underscores the critical importance of early screening, timely intervention, and broader public health awareness to address this hidden but escalating health threat.
Time of India
a day ago
- Time of India
This disease might be silently killing millions quietly, says research. Are you at risk?
A recent international study has revealed that millions of people in the US and Europe may be unknowingly living with a dangerous form of fatty liver disease. Published in The Lancet Regional Health Europe, the research indicates that a vast number of individuals are affected by metabolic dysfunction-associated steatotic liver disease (MASLD), with the majority still undiagnosed. Widespread but Largely Undetected The study examined populations in the United States, United Kingdom, Germany, and France, and found that approximately 20 million people across these countries have the more severe variant of MASLD known as metabolic dysfunction-associated steatohepatitis (MASH). Alarmingly, only about 2.5 million have received a formal diagnosis. This means roughly three-quarters of those with the disease—an estimated 16.7 million individuals—remain unaware of their condition. MASLD is the updated term for non-alcoholic fatty liver disease (NAFLD), and it affects people whose liver contains over 5% fat despite little or no alcohol intake. While many patients only develop the earliest and less severe stage known as simple fatty liver, the disease can progress without symptoms and cause serious damage over time. Progressive and Potentially Fatal MASH, the aggressive form of the disease, is associated with inflammation and can lead to fibrosis, or scarring of the liver. If not managed, it may progress to cirrhosis, a stage marked by irreversible liver damage and potential liver failure. The condition is also linked to higher risks of cardiovascular issues, chronic kidney disease, and liver cancer. The study's findings emphasize the urgency of early diagnosis, especially as MASH is particularly common among people with type 2 diabetes and those who are overweight or obese. Researchers noted that around two-thirds of individuals with type 2 diabetes are thought to have MASLD. Urgent Need for Diagnosis and Treatment Dr. Jeffrey Lazarus, the lead author of the study, stressed the economic and health burden posed by undiagnosed MASH. He pointed out that without a significant increase in diagnosis and treatment, the financial costs to healthcare systems could triple over the next two decades. Prof. Emmanouil Tsochatzis of University College London echoed this warning, stating that over 15 million people in the US and Europe are living with the most severe form of fatty liver disease without knowing it. He warned that both human suffering and economic consequences could worsen significantly if diagnosis rates do not improve. Traditionally, MASH has been diagnosed through liver biopsy, but newer, non-invasive tools such as blood tests, ultrasound, and MRI scans have made screening easier. Experts now recommend that individuals with type 2 diabetes, obesity combined with other risk factors, or persistently elevated liver enzymes undergo regular screening. Potential Role of Weight Loss Medications The study has also brought renewed attention to the potential of weight loss medications to help manage MASH. Dr. Paul Brennan, a hepatologist and co-author of the study, highlighted the promise of GLP-1 agonists like Wegovy and Mounjaro. These drugs work by reducing appetite and slowing digestion, leading to weight loss, which in turn may help reduce fat accumulation and scar tissue in the liver. Michael Betel, president of the Fatty Liver Alliance, stressed that individuals with type 2 diabetes or obesity are often not screened for MASH until significant liver damage has occurred. He called for broader liver health assessments and, when appropriate, the use of weight loss drugs as part of a comprehensive treatment strategy. A separate study released around the same time found that the diabetes drug dapagliflozin not only helps reduce blood sugar but also lowers fat and scarring in the liver, suggesting another potential treatment pathway. Risk Factors and Screening According to health authorities like the NHS, those at greater risk of MASLD include people who are overweight, have type 2 diabetes, high blood pressure, high cholesterol, metabolic syndrome, or are over the age of 50. Smoking and thyroid disorders may also increase the risk. Doctors typically begin diagnosis with blood tests that show elevated liver enzymes. If abnormalities are detected, further assessments such as imaging scans or liver elastography (FibroScan) are used to evaluate liver fat and fibrosis levels. With the growing prevalence of MASLD and MASH, the study underscores the critical importance of early screening, timely intervention, and broader public health awareness to address this hidden but escalating health threat.
